NEW YORK (GenomeWeb) – Researchers from the Phase III EURTAC study have published a secondary analysis demonstrating high sensitivity and specificity of blood-based EGFR testing compared to the initial tissue testing performed in the trial.

The study also supports growing evidence that the type of EGFR mutation a patient has, either in tumor tissue or in circulating DNA, may be associated with much different responses to the EGFR inhibitors.